181 related articles for article (PubMed ID: 21410455)
1. Carvedilol targets human K2P 3.1 (TASK1) K+ leak channels.
Staudacher K; Staudacher I; Ficker E; Seyler C; Gierten J; Kisselbach J; Rahm AK; Trappe K; Schweizer PA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2011 Jul; 163(5):1099-110. PubMed ID: 21410455
[TBL] [Abstract][Full Text] [Related]
2. Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.
Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2012 Oct; 385(10):1003-16. PubMed ID: 22790794
[TBL] [Abstract][Full Text] [Related]
3. The human cardiac K2P3.1 (TASK-1) potassium leak channel is a molecular target for the class III antiarrhythmic drug amiodarone.
Gierten J; Ficker E; Bloehs R; Schweizer PA; Zitron E; Scholz E; Karle C; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2010 Mar; 381(3):261-70. PubMed ID: 19777211
[TBL] [Abstract][Full Text] [Related]
4. Class I antiarrhythmic drugs inhibit human cardiac two-pore-domain K(+) (K2 ₂p) channels.
Schmidt C; Wiedmann F; Schweizer PA; Becker R; Katus HA; Thomas D
Eur J Pharmacol; 2013 Dec; 721(1-3):237-48. PubMed ID: 24070813
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cardiac two-pore-domain K+ (K2P) channels by the antiarrhythmic drug vernakalant--comparison with flecainide.
Seyler C; Li J; Schweizer PA; Katus HA; Thomas D
Eur J Pharmacol; 2014 Feb; 724():51-7. PubMed ID: 24374008
[TBL] [Abstract][Full Text] [Related]
6. Vernakalant activates human cardiac K(2P)17.1 background K(+) channels.
Seyler C; Schweizer PA; Zitron E; Katus HA; Thomas D
Biochem Biophys Res Commun; 2014 Aug; 451(3):415-20. PubMed ID: 25108155
[TBL] [Abstract][Full Text] [Related]
7. Regulation of two-pore-domain (K2P) potassium leak channels by the tyrosine kinase inhibitor genistein.
Gierten J; Ficker E; Bloehs R; Schlömer K; Kathöfer S; Scholz E; Zitron E; Kiesecker C; Bauer A; Becker R; Katus HA; Karle CA; Thomas D
Br J Pharmacol; 2008 Aug; 154(8):1680-90. PubMed ID: 18516069
[TBL] [Abstract][Full Text] [Related]
8. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation.
Seyler C; Duthil-Straub E; Zitron E; Gierten J; Scholz EP; Fink RH; Karle CA; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2012 Mar; 165(5):1467-75. PubMed ID: 21838752
[TBL] [Abstract][Full Text] [Related]
9. Modulation of K2P 2.1 and K2P 10.1 K(+) channel sensitivity to carvedilol by alternative mRNA translation initiation.
Kisselbach J; Seyler C; Schweizer PA; Gerstberger R; Becker R; Katus HA; Thomas D
Br J Pharmacol; 2014 Dec; 171(23):5182-94. PubMed ID: 25168769
[TBL] [Abstract][Full Text] [Related]
10. Antiarrhythmic drug carvedilol inhibits HERG potassium channels.
Karle CA; Kreye VA; Thomas D; Röckl K; Kathöfer S; Zhang W; Kiehn J
Cardiovasc Res; 2001 Feb; 49(2):361-70. PubMed ID: 11164846
[TBL] [Abstract][Full Text] [Related]
11. New Targets for Old Drugs: Cardiac Glycosides Inhibit Atrial-Specific K
Schmidt C; Wiedmann F; Gaubatz AR; Ratte A; Katus HA; Thomas D
J Pharmacol Exp Ther; 2018 Jun; 365(3):614-623. PubMed ID: 29643254
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic TWIK-Related Acid-Sensitive K+ Channel (TASK-1) Potassium Channel Inhibitor A293 Facilitates Acute Cardioversion of Paroxysmal Atrial Fibrillation in a Porcine Large Animal Model.
Wiedmann F; Beyersdorf C; Zhou X; Büscher A; Kraft M; Nietfeld J; Walz TP; Unger LA; Loewe A; Schmack B; Ruhparwar A; Karck M; Thomas D; Borggrefe M; Seemann G; Katus HA; Schmidt C
J Am Heart Assoc; 2020 May; 9(10):e015751. PubMed ID: 32390491
[TBL] [Abstract][Full Text] [Related]
13. Identification and functional characterization of zebrafish K(2P)10.1 (TREK2) two-pore-domain K(+) channels.
Gierten J; Hassel D; Schweizer PA; Becker R; Katus HA; Thomas D
Biochim Biophys Acta; 2012 Jan; 1818(1):33-41. PubMed ID: 21963410
[TBL] [Abstract][Full Text] [Related]
14. Cardiac K
Staudacher I; Seehausen S; Illg C; Lugenbiel P; Schweizer PA; Katus HA; Thomas D
Prog Biophys Mol Biol; 2019 Jul; 144():128-138. PubMed ID: 31182191
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular pharmacology of K
Staudacher I; Illg C; Chai S; Deschenes I; Seehausen S; Gramlich D; Müller ME; Wieder T; Rahm AK; Mayer C; Schweizer PA; Katus HA; Thomas D
Naunyn Schmiedebergs Arch Pharmacol; 2018 Oct; 391(10):1119-1131. PubMed ID: 30008082
[TBL] [Abstract][Full Text] [Related]
16. Carvedilol blocks the cloned cardiac Kv1.5 channels in a β-adrenergic receptor-independent manner.
Jeong I; Choi BH; Yoon SH; Hahn SJ
Biochem Pharmacol; 2012 Feb; 83(4):497-505. PubMed ID: 22146582
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
[TBL] [Abstract][Full Text] [Related]
18. Effects of carvedilol on transient outward and ultra-rapid delayed rectifier potassium currents in human atrial myocytes.
Deng C; Yu X; Kuang S; Zhang W; Zhou Z; Zhang K; Qian W; Shan Z; Yang M; Wu S; Lin S
Life Sci; 2007 Jan; 80(7):665-71. PubMed ID: 17118405
[TBL] [Abstract][Full Text] [Related]
19. Carvedilol blocks the repolarizing K+ currents and the L-type Ca2+ current in rabbit ventricular myocytes.
Cheng J; Niwa R; Kamiya K; Toyama J; Kodama I
Eur J Pharmacol; 1999 Jul; 376(1-2):189-201. PubMed ID: 10440104
[TBL] [Abstract][Full Text] [Related]
20. Open channel block of Kv3.1 currents by fluoxetine.
Sung MJ; Ahn HS; Hahn SJ; Choi BH
J Pharmacol Sci; 2008 Jan; 106(1):38-45. PubMed ID: 18187934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
